IPO Issue Details
Issue Price / Price Band₹679 per share (Fixed Price)
Face Value₹2 Per Share
Lot Size22 Shares per Lot
Total Issue Size2,73,68,143 shares (aggregating up to ₹1,856.74 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenTue, 30 Jul 2024
Subscription CloseThu, 01 Aug 2024
Anchor AllotmentMon, 29 Jul 2024
Basis of AllotmentFri, 02 Aug 2024
Initiation of RefundsMon, 05 Aug 2024
Credit of Shares to DematMon, 05 Aug 2024
Listing DateTue, 06 Aug 2024
UPI Mandate Deadline2024-08-01
Application & Investment Details
Retail — Min (1 Lots)₹14,938 — 22 shares
Retail — Max (13 Lots)₹194,194 (13 Lots)
HNI — Min (14 Lots)₹2,09,132 — 308 shares
Pre-IPO Promoter Holding14,73,56,280 shares
Post-IPO Promoter Holding15,73,71,007 shares
Fresh Issue Shares1,00,37,708 shares (aggregating up to ₹680.99 Cr)
Offer for Sale Shares1,73,30,435 shares of ₹2 (aggregating up to ₹1,175.75 Cr)
About Akums Drugs & Pharmaceuticals Ltd.
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.
Objects of the Issue
Akums Drugs & Pharmaceuticals Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
Repayment/ prepayment of indebtedness of the company and its Subsidiaries;
2
Funding incremental working capital requirements of the company;
3
Pursuing inorganic growth initiatives through acquisitions; and
4
General corporate purposes.
Shareholding & Lock-in
Pre-IPO Promoter Holding
14,73,56,280 shares
Post-IPO Promoter Holding
15,73,71,007 shares
Lock-in Period (30%)September 1, 2024
Lock-in Period (50%)October 31, 2024